Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Thompson, ER; Nguyen, T; Kankanige, Y; Markham, JF; Anderson, MA; Handunnetti, SM; Thijssen, R; Yeh, PS; Tam, CS; Seymour, JF; Roberts, AW; Westerman, DA; Blombery, P

Author(s): Thompson, ER; Nguyen, T; Kankanige, Y; Markham, JF; Anderson, MA; Handunnetti, SM; Thijssen, R; Yeh, PS; Tam, CS; Seymour, JF; Roberts, AW; Westerman, DA; Blombery, P;
Details: Publication Year 2022-01-25,Volume 6,Issue #2,Page 503-508
Journal Title: Blood Advances
Abstract: The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex and often heterogeneous at the patient level. To gain insight into the clonal architecture of acquired genomic resistance to Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors in CLL, particularly in patients carrying multiple resistance mutations, we performed targeted single-cell DNA sequencing of 8 patients who developed progressive disease (PD) on TAs (either class). In all cases, analysis of single-cell architecture revealed mutual exclusivity between multiple resistance mutations to the same TA class, variable clonal co-occurrence of multiple mutations affecting different TAs in patients exposed to both classes, and a phenomenon of multiple independent emergences of identical nucleotide changes leading to canonical resistance mutations. We also report the first observation of established BCL2 resistance mutations in a patient with mantle cell lymphoma (MCL) following PD on sequential monotherapy, implicating BCL2 as a venetoclax resistance mechanism in MCL. Taken together, these data reveal the significant clonal complexity of CLL and MCL progression on TAs at the nucleotide level and confirm the presence of multiple, clonally independent, mechanisms of TA resistance within each individual disease context.
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 34861696
Publisher's Version: https://doi.org/10.1182/bloodadvances.2021006211
Open Access at Publisher's Site: https://doi.org/10.1182/bloodadvances.2021006211
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2022-02-18 11:34:09

Last Modified: 2022-02-18 02:55:16